Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates

American Journal of Public Health

Volumn 104, Issue 12, 2014, Pages 2439-2444

  Nowak, Sarah A ^a   Parker, Andrew M ^a  

^a RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; DECISION MAKING; EARLY DIAGNOSIS; FEMALE; HUMAN; MAMMOGRAPHY; QUESTIONNAIRE; RADIOGRAPHY; SOCIAL SUPPORT; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

BREAST NEOPLASMS; DECISION MAKING; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MODELS, THEORETICAL; SOCIAL SUPPORT; SURVEYS AND QUESTIONNAIRES;

EID: 84911166991     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2014.302153     Document Type: Review

References (36)

1. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst. 2009;101(17): 1216-1220.
2. Chamot E, Perneger T. Misconceptions about efficacy of mammography screening: A public health dilemma. J Epidemiol Community Health. 2001;55(11): 799-803.
3. Domenighetti G, D'Avanzo B, Egger M, et al. Women's perception of the benefits of mammography screening: Population-based survey in four countries. Int J Epidemiol. 2003;32(5): 816-821.
4. McQueen A, Kreuter MW. Women's cognitive and affective reactions to breast cancer survivor stories: A structural equation analysis. Patient Educ Couns. 2010; 81: S15-S21.
5. Larson RJ, Woloshin S, Schwartz LM, Welch HG. Celebrity endorsements of cancer screening. J Natl Cancer Inst. 2005;97(9): 693-695.
6. Chapman S, McLeod K, Wakefield M, Holding S. Impact of news of celebrity illness on breast cancer screening: Kylie Minogue's breast cancer diagnosis. Med J Aust. 2005;183(5): 247-250.
7. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1): 71-78.
8. Welch HG, Frankel BA. Likelihood that a woman with screen-detected breast cancer has had her "life saved" by that screening. Arch Intern Med. 2011;171(22): 2043-2046.
9. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: Update 2003. CA Cancer J Clin. 2003;53(3): 141-169.
10. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10): 716-726.
11. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997. CA Cancer J Clin. 1997; 47(3): 154-160.
12. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2): 120-134.
13. RAND American Life Panel. September 9, 2012. Available at: Https://mmicdata.rand.org/alp. Accessed February 1, 2013.
14. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. The SPECTRUM population model of the impact of screening and treatment on US breast cancer trends from 1975 to 2000: Principles and practice of themodelmethods. J Natl Cancer Inst Monogr. 2006;2006(36): 47-55.
15. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr. 2006;2006(36): 37-47.
16. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JDF. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006;2006(36): 56-65.
17. Hanin LG, Miller A, Zorin A, Yakovlev AY. The University of Rochester model of breast cancer detection and survival. J Natl Cancer Inst Monogr. 2006;2006 (36): 66-78.
18. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of US breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006;2006(36): 86-95.
19. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on US breast cancer mortality: A Bayesian approach. J Natl Cancer Inst Monogr. 2006;2006(36): 30-36.
20. Meissner HI, Breen N, Taubman ML, Vernon SW, Graubard BI. Which women aren't getting mammograms and why? (United States). Cancer Causes Control. 2007; 18(1): 61-70.
21. Maxwell CJ, Bancej CM, Snider J. Predictors of mammography use among Canadian women aged 50-69: Findings from the 1996/97 National Population Health Survey. CMAJ. 2001;164(3): 329-334.
22. Mayne L, Earp J. Initial and repeat mammography screening: Different behaviors/different predictors. J Rural Health. 2003;19(1): 63-71.
23. Sabatino SA, Coates RJ, Uhler RJ, Breen N, Tangka F, Shaw KM. Disparities in mammography use among US women aged 40-64 years, by race, ethnicity, income, and health insurance status, 1993 and 2005. Med Care. 2008;46(7): 692-700.
24. Rodríguez MA, Ward LM, Pérez-Stable EJ. Breast and cervical cancer screening: Impact of health insurance status, ethnicity, and nativity of Latinas. Ann Fam Med. 2005;3(3): 235-241.
25. Hsia J, Kemper E, Kiefe C, et al. The importance of health insurance as a determinant of cancer screening: Evidence from the Women's Health Initiative. Prev Med. 2000;31(3): 261-270.
26. Calle EE, Flanders WD, Thun MJ, Martin LM. Demographic predictors of mammography and Pap smear screening in US women. Am J Public Health. 1993; 83(1): 53-60.
27. O'Malley MS, Earp JA, Hawley ST, Schell MJ, Mathews HF, Mitchell J. The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: Who gets the message about breast cancer screening? Am J Public Health. 2001;91(1): 49-54.
28. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21): 1998-2005.
29. Granovetter M. The strength of weak ties: A network theory revisited. Sociol Theory. 1983;1(1): 201-233.
30. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17): 1784-1792.
31. McMahon PM, Hazelton WD, Kimmel M, Clarke LD. CISNET lung models: Comparison of model assumptions and model structures. Risk Anal. 2012;32(suppl 1): S166-S178.
32. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10): 738-747.
33. Gulati R, Wever EM, Tsodikov A, et al. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 2011;20(5): 740-750.
34. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2): 175-181.
35. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19): 1325-1329.
36. Hubbard RA, Johnson E, Hsia R, Rutter CM. The cumulative risk of false-positive fecal occult test after 10 years of screening. Cancer Epidemiol Biomarkers Prev. 2013;22(9): 1612-1619.